Unique ID issued by UMIN | UMIN000044194 |
---|---|
Receipt number | R000050462 |
Scientific Title | Prospective observational study of correlation between hematopoietic cell infusion-related adverse events and post-transplant complications. |
Date of disclosure of the study information | 2021/06/30 |
Last modified on | 2021/11/15 12:55:17 |
Prospective observational study of correlation between hematopoietic cell infusion-related adverse events and post-transplant complications.
Prospective observational study of correlation between hematopoietic cell infusion-related adverse events and post-transplant complications.
Prospective observational study of correlation between hematopoietic cell infusion-related adverse events and post-transplant complications.
Prospective observational study of correlation between hematopoietic cell infusion-related adverse events and post-transplant complications.
Japan |
Recipient of hematopoietic stem cell transplantation
Hematology and clinical oncology | Blood transfusion |
Malignancy
NO
We will clarify the impact of adverse events associated with hematopoietic stem cell transplantation (HSCT) on survival and the incidence of various complications after HSCT.
In addition, we will provide basic data for the establishment of a biovigilance system for HSCT in the future.
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
Incidence of complications (PIR, Engraftment failure, TMA, VOD/SOS, GVHD, or Viral Infection) at 100 days after transplantation in association with hematopoietic cell infusion-related adverse events.
2-year overall survival by incidences of hematopoietic cell infusion-related adverse events
Observational
15 | years-old | <= |
Not applicable |
Male and Female
All allogenic hematopoietic stem cell infusion performed on 15 years of age or older at participating institution.
(1)Patients whose consent for this study are not available.
(2)Patient who disagree to the survey Transplant Registry Unified Management Program.
(3)Donor Lymphocyte Infusion
(4) Autologous transplantation
(5) Other patients who are judged by the physician in charge to be inappropriate for this study.
600
1st name | kazuhiko |
Middle name | |
Last name | ikeda |
Fukushima Medical University
Department of Blood Transfusion and Transplantation Immunology
960-1295
Hikarigaoka 1, Fukushima, Fukushima, Japan
024-547-1536
kazu-ike@fmu.ac.jp
1st name | Keiji |
Middle name | |
Last name | Minakawa |
Fukushima Medical University Hospital
Department of Blood Transfusion and Transplantation Immunology
960-1295
Hikarigaoka 1,Fukushima, Fukushima, Japan
024-547-1536
inf-hsct@fmu.ac.jp
Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University
KYOKUTO PHARMACEUTICAL INDUSTRIAL CO., LTD
Profit organization
Japan
Fukushima Medical University
Hikarigaoka 1, Fukushima, Fukushima, Japan
024-547-1111
inf-hsct@fmu.ac.jp
NO
福島県立医科大学附属病院
2021 | Year | 06 | Month | 30 | Day |
Unpublished
Enrolling by invitation
2021 | Year | 01 | Month | 18 | Day |
2021 | Year | 03 | Month | 16 | Day |
2021 | Year | 04 | Month | 01 | Day |
2026 | Year | 03 | Month | 31 | Day |
prospective observational study
2021 | Year | 05 | Month | 12 | Day |
2021 | Year | 11 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050462
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |